Sign Up Today and Learn More About ORIC Pharmaceuticals Stock
Invest in or calculate the value of your shares in ORIC Pharmaceuticals or other pre-IPO companies through EquityZen's platform.
About ORIC Pharmaceuticals Stock
Founded
2014
Headquarters
South San Francisco, CA, US
Total Funding
178M
Industries
Science and Engineering, Health Care, Biotechnology
ORIC Pharmaceuticals is a privately-held company dedicated to discovering and developing novel therapies for treatment-resistant cancers. While recent advances with targeted therapeutics have extended prognoses in many disease settings, cancers often develop resistance to current drugs. Relapsed patients lack further treatment options. ORIC has assembled a world-class scientific team dedicated to the discovery of therapies that can meaningfully improve clinical outcomes for these patients.
ORIC Pharmaceuticals Press Mentions
Stay in the know about the latest news on ORIC Pharmaceuticals
ORIC Pharmaceuticals Announces Initiation of Phase 1b Study with ORIC-101 in Patients with Cancer
businesswire • May 13, 2019
ORIC Pharmaceuticals Appoints Jacob Chacko CEO
xconomy • May 21, 2018
ORIC Pharmaceuticals Announces $50 Million Series C Financing to Support Novel Therapies for Treatment-Resistant Cancers
prnewswire • Feb 21, 2018
ORIC Has Appointed Rich Heyman, PhD as Acting Chief Executive Officer and Leonard Reyno, MD as Chief Medical Officer
prnewswire • Dec 20, 2017
Investors in ORIC Pharmaceuticals
Discover investors in ORIC Pharmaceuticals stock and explore their portfolio companies
ORIC Pharmaceuticals Management
Leadership team at ORIC Pharmaceuticals
Chief Executive Officer
Jacob Chacko
Chief Scientific Officer
Lori Friedman
Join now and verify your accreditation status to gain access to:
- ORIC Pharmaceuticals current valuation
- ORIC Pharmaceuticals stock price
- Available deals in ORIC Pharmaceuticals and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
How to invest in ORIC Pharmaceuticals stock?
Accredited investors can buy pre-IPO stock in companies like ORIC Pharmaceuticals through EquityZen funds. These investments are made available by existing ORIC Pharmaceuticals shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell ORIC Pharmaceuticals stock?
Shareholders can sell their ORIC Pharmaceuticals stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
